Research Reports

Key takeaways

Revenue increased 28.1% to $40.8M from $31.8M, driven by higher Galleri test volumes.

Operating loss improved 11.6% to -$135.8M from -$153.6M, reflecting cost optimization and fixed cost leverage.

Net loss narrowed 12.3% to -$93.2M from -$106.2M, with diluted EPS improving to -$2.29 from -$3.10.

Free cash flow was -$87.5M, as operating cash outflows of -$86.9M were partially offset by capital expenditures of $0.5M.

The company anticipates needing additional financing to fund future operations.

Full analysis

Revenue Growth Driven by Galleri Volume

Operating Loss Improvement Through Cost Discipline

Cash Flow and Liquidity Position

Outlook and Key Catalysts

The company continues to invest in commercialization and FDA approval for Galleri. The decrease in cost of screening revenue as a percentage of revenue reflects operational efficiencies, but the ASP decline highlights pricing pressures. The company's tax returns remain open for examination by federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits. Management expects to need additional financing to support ongoing operations and growth initiatives.